GPE
Eli Lilly’s State Law Attempt to Halt Florida Compounding Pharmacy’s Tirzepatide Sales Dismissed
Eli Lilly, Florida compounding pharmacy, RXCompoundStore.com, Tirzepatide (Mounjaro/ Zepbound), Judge Roy Altman, Federal Food/ Drug/ and Cosmetic Act (FDCA), Frivolous lawsuits
Sanofi Resolves 4,000 Zantac Cancer Claims in US State Courts
Sanofi, Zantac, Heartburn Drug, Cancer Lawsuits, Settlement Agreement, US State Courts
Genmab Acquires ProfoundBio for $1.8 Billion to Challenge AbbVie’s Elahere in ADC Market
Genmab, ProfoundBio, $1.8 billion acquisition, Antibody Drug Conjugates (ADCs), Competition with AbbVie’s Elahere, Rinatabart sesutecan (Rina-S), Folate Receptor Alpha (FRα), Midphase clinical trials
Walgreens Takes $6 Billion Hit from VillageMD Investment Amid Strategic Review
Walgreens, VillageMD, Quarter 2, $6 billion loss, Write-down, Investment Value Decline, Strategic Review, Cost Savings Plan, Underperforming Clinics Closure
FDA Grants Emergency Authorization for Invivyd’s Pemgarda Antibody Prophylactic Against COVID-19 in Immunocompromised Individuals
Invivyd, Pemgarda (pemivibart; formerly VYD222), Half-Life Extended Monoclonal Antibody, COVID-19 Prophylactic, Immunocompromised Patients, Emergency Use Authorization (EUA), FDA Approval, Moderate to Severe Immune Compromise, Pre-exposure Prophylaxis (Prevention) of COVID-19 in Adults/ Adolescents
Orchard Therapeutics Sets $4.25 Million Price Tag for Leukodystrophy Gene Therapy
Orchard Therapeutics, Leukodystropy, Gene Therapy, Lenmeldy, $4.25 million US price tag
FDA Greenlights Idorsia’s Aprocitentan (Tryvio) for Resistant Hypertension Patients
FDA approval, Idorsia, Aprocitentan, Tryvio, Resistant hypertension, Endothelin receptor antagonist, Systolic blood pressure, Uncontrolled hypertension, Combination therapy, Clinical trials, PRECISION study, Recommended dosage: 12.5 mg, Availability: Second half of 2024, Edema and fluid retention side effects
Bayer’s Menopause Drug Elinzanetant Achieves Successful Long-Term Results in Phase III Trial, Rivalling Astellas’ Veozah
Bayer, Elinzanetant, Menopause drug, Phase III trial, Long-term results, Hot flashes, Vasomotor symptoms, Astellas, Veozah, Competition
FDA Grants First Approval for Orchard Therapeutics’ Gene Therapy Lenmeldy in Treating Rare Pediatric Neuron Disease
Orchard Therapeutics, Lenmeldy, FDA Approval, Metachromatic Leukodystrophy (MLD), Rare Pediatric Disease, Autologous Gene Therapy, Pre-Symptomatic Late Infantile/ Early Juvenile Patients
FDA Grants Accelerated Approval to Madrigal’s Rezdiffra for MASH Treatment
FDA approval, Madrigal Pharmaceuticals, Rezdiffra (resmetirom), Metabolic dysfunction-associated steatohepatitis (MASH), Accelerated clearance, Adult patients with non-cirrhotic MASH and moderate-to-advanced liver fibrosis